載入中
NASDAQHealthcareBiotechnology
最新資料
US$471.75
−US$5.16 · -1.08%
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
前收盤價
US$471.75
−US$5.16 · -1.08%
盤中時間採用ET。市場資料可能有所延遲。
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
日內區間
目前US$471.75
52週區間
目前US$471.75
盤中時間採用ET。市場資料可能有所延遲。
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
日內區間
目前US$471.75
52週區間
目前US$471.75
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 9.58億 USD | 1.8億 USD | — | — | — |
| 銷貨成本 | 5614.8萬 USD | 623.3萬 USD | — | — | — |
| 毛利 | 9.02億 USD | 1.74億 USD | — | — | — |
| 研究與開發 | 3.89億 USD | 2.37億 USD | 2.72億 USD | 2.45億 USD | 2.05億 USD |
| 銷售、一般及管理費用 | 8.14億 USD | 4.35億 USD | 1.08億 USD | 4813萬 USD | 3731.8萬 USD |
| 營業費用 | 12.02億 USD | 6.72億 USD | 3.8億 USD | 2.94億 USD | 2.42億 USD |
| 利息收入 | 3736.4萬 USD | 4665.4萬 USD | 1957.8萬 USD | 218.5萬 USD | 36.3萬 USD |
| 利息支出 | 2230.9萬 USD | 1467.1萬 USD | 1271.2萬 USD | 396.4萬 USD | — |
| 折舊和攤銷 | 150.6萬 USD | 109.6萬 USD | 52.7萬 USD | 46.7萬 USD | 40.5萬 USD |
| 營業利益 | −3億 USD | −4.98億 USD | −3.8億 USD | −2.94億 USD | −2.42億 USD |
| 淨利 | −2.88億 USD | −4.66億 USD | −3.74億 USD | −2.95億 USD | −2.42億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$680.38
上漲空間 44.22%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.17億0.01%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2.29億0.12%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.32億0.29%447億 USD0.05%US$344.74+1.22%
State Street SPDR S&P Biotech ETFXBI1.31億1.32%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF1.19億0.12%954億 USD0.05%US$235+0.80%
First Trust NYSE Arca Biotechnology Index FundFBT7957.9萬2.75%28.91億 USD0.55%US$265.4+2.00%
iShares Biotechnology ETFIBB7953.09萬0.76%108.2億 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA5024.23萬0.23%218.24億 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
